Current Headlines

  1. Takeda, Monash Partner To Develop Gastrointestinal Treatments
    12/12/2014

    Monash University, Australia's largest university, has entered into a partnership with Takeda to develop treatments for gastroenterology diseases and conditions.

  2. Southern Biologics Network Launches To Develop Biological Treatments
    12/12/2014

    A public-private partnership, Southern Biologics Network (SBN), has launched in Alabama, North Carolina, and Louisiana to develop biological treatments.

  3. Harvard Research Finds Potential 3D Cancer Vaccine
    12/12/2014

    Researchers at Harvard University have discovered a way to inject programmable biomaterial which assembles into 3D structures after the injection.

  4. Novartis' Jakavi Safe And Effective In Phase 3B Myelofibrosis Trial
    12/11/2014

    Novartis reported that its blood cancer drug Jakavi (ruxolitinib) was safe and effective in treating patients with myelofibrosis in a Phase 3B trial.

  5. Pfizer Inks Gene Therapy Partnership With Spark Therapeutics
    12/11/2014

    Pfizer announced two major moves that will expand its rare disease R&D activities. First, the company said it will establish a gene therapy platform through its newly inked agreement with Spark Therapeutics. Secondly, it has appointed Dr. Michael Linden, Director of the University College London Gene Therapy Consortium, as head of Pfizer’s gene therapy research in rare diseases area.

  6. Sunovion Files sNDA With FDA For Aptiom In Seizures
    12/11/2014

    Sunovion Pharmaceuticals announced its filing of a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) for its drug Aptiom (eslicarbazepine acetate) as monotherapy for partial-onset seizures.

  7. Antibiotic Giant Cubist Acquired by Merck In $9.5 B Deal
    12/11/2014

    Massachusetts-based company Cubist Pharmaceuticals has announced that Merck will be acquiring Cubist in a deal valued at about $9.5 billion.

  8. Pharmacyclics’ Imbruvica Shows Potential In Multiple Myeloma
    12/10/2014

    Pharmacyclics reported new Phase 2 data for Imbruvica (ibrutunib) as treatment for relapsed or relapsed/refractory multiple myeloma (MM).

  9. Seattle Genetics, Takeda Report Positive Adcetris Data In Lymphoma Studies
    12/10/2014

    Seattle Genetics and Takeda Pharmaceutical Company report positive results from Adcetris studies to treat lymphoma.

  10. Novartis Posts Positive CTL019 Data In r/r ALL
    12/10/2014

    Novartis revealed strong clinical data for its investigational chimeric antigen receptor (CAR) therapy CTL019 as treatment for relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.